Michael Patrick Boyle, M.D.
Assistant Professor of Medicine
Director, Adult Cystic Fibrosis Program
The Johns Hopkins Medical Institutions
Division of Pulmonary and Critical Care Medicine
1830 East Monument Street, 5th floor
Baltimore, MD 21205
Phone: (410) 502-7044
Fax: (410) 502-7048
Email: mboyle@jhmi.edu

Michael Boyle

Weisman HF, Bartow T, Leppo MK, Marsh HC, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis. Science 249:146-151, 1990.

Weisman HF, Bartow T, Leppo MK, Boyle MP, Marsh HC, Carson GR, Roux KH, Weisfeldt ML, Fearon DT. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans Assoc Am Physicians 103:64-72, 1990.

Boyle MP. Minocycline Induced Pancreatitis in Cystic Fibrosis. Chest 119:1283-1285, 2001.

Boyle MP. The Spectrum of CFTR-related disease. Internal Medicine 40(7): 522-525, 2001.

Boyle MP, Enke RA, Adams RJ, Guggino WB, Zeitlin PL. In-Utero AAV-Mediated Gene Transfer to Rabbit Pulmonary Epithelium. Molecular Therapy 4: 115-121, 2001.

Noone PG, Hamblett N, Accurso F, Aitken ML, Boyle MP, Dovey M, Gibson R, Johnson C, Kellerman D, Konstan MW, Milgram L, Mundahl J, Retsch-Bogort G, Rodman D, Williams-Warren J, Wilmott RW, Zeitlin P, Ramsey B. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: Results of a phase I multi-center study. Pediatric Pulmonology 32: 122-8, 2001.

Boyle MP, Farukhi Z, Nosky ML. Strategies for Improving Transition to Adult Cystic Fibrosis Care Based on Patient and Parent Views. Pediatric Pulmonology 32:428-436, 2001.

Zeitlin PL, Diener-West M, Rubenstein R, Boyle MP, Lee C, Brass-Ernst L. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Molecular Therapy 6: 119-126, 2002.

Publications Next